ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.
Also NCI prostate SPOREs plan biospecimen bank.
NCI advisors seek comment on clinical trials system, until Jan. 15.
NCI funds 17 EDRN biomarker labs. Bush signs omnibus funding legislation.
Dept. of Defense opens program announcements for prostate cancer research.
Children’s Cancer Research Institute at UT Health Science Center recruits faculty.
Two cancer center directors named: Michael Kastan at St. Jude, James Willson at Harold Simmons.
December issue of Business & Regulatory Report included (an additional 8 pages of industry news).
Next issue of The Cancer Letter is scheduled for Jan. 7, 2005.
Trending Stories
- Duke brain cancer researcher Kyle Walsh named director of NIEHS
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer
- Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research









